JP2005528351A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005528351A5 JP2005528351A5 JP2003574110A JP2003574110A JP2005528351A5 JP 2005528351 A5 JP2005528351 A5 JP 2005528351A5 JP 2003574110 A JP2003574110 A JP 2003574110A JP 2003574110 A JP2003574110 A JP 2003574110A JP 2005528351 A5 JP2005528351 A5 JP 2005528351A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- mixtures
- chelating agent
- activated protein
- diluent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 10
- 101800004937 Protein C Proteins 0.000 claims 6
- 102100036546 Salivary acidic proline-rich phosphoprotein 1/2 Human genes 0.000 claims 6
- 101800001700 Saposin-D Proteins 0.000 claims 6
- 239000002738 chelating agent Substances 0.000 claims 6
- 239000003085 diluting agent Substances 0.000 claims 6
- 229960000856 protein c Drugs 0.000 claims 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 238000009472 formulation Methods 0.000 claims 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 2
- 229930195725 Mannitol Natural products 0.000 claims 2
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 2
- 239000003978 infusion fluid Substances 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- 239000000594 mannitol Substances 0.000 claims 2
- 235000010355 mannitol Nutrition 0.000 claims 2
- 239000001103 potassium chloride Substances 0.000 claims 2
- 235000011164 potassium chloride Nutrition 0.000 claims 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 2
- 239000001488 sodium phosphate Substances 0.000 claims 2
- 229910000162 sodium phosphate Inorganic materials 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 claims 2
- 239000000945 filler Substances 0.000 claims 1
- 239000012931 lyophilized formulation Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36336402P | 2002-03-08 | 2002-03-08 | |
| PCT/US2003/005046 WO2003075834A2 (en) | 2002-03-08 | 2003-02-27 | Activated protein c formulations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005528351A JP2005528351A (ja) | 2005-09-22 |
| JP2005528351A5 true JP2005528351A5 (enExample) | 2006-04-13 |
Family
ID=27805279
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003574110A Pending JP2005528351A (ja) | 2002-03-08 | 2003-02-27 | 活性化プロテインc製剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20050143283A1 (enExample) |
| EP (1) | EP1485121A4 (enExample) |
| JP (1) | JP2005528351A (enExample) |
| AU (1) | AU2003213146A1 (enExample) |
| CA (1) | CA2475738A1 (enExample) |
| WO (1) | WO2003075834A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101438839B1 (ko) * | 2006-04-14 | 2014-10-02 | 맨카인드 코포레이션 | 글루카곤 유사 펩타이드 1 (glp-1) 약제학적 제제 |
| EP2242875A4 (en) * | 2008-01-15 | 2012-04-04 | Univ British Columbia | PROTEIN-C-RS2069915 AS RESPONSE PREDICTOR FOR SURVIVAL RATE AND ADMINISTRATION OF AN ACTIVATED PROTEIN-C OR PROTEIN-C-SIMILAR COMPOUND |
| WO2012068519A2 (en) | 2010-11-19 | 2012-05-24 | Sirius Genomics Inc. | Markers associated with response to activated protein c administration, and uses thereof |
| KR20150110607A (ko) * | 2013-01-14 | 2015-10-02 | 아페이론 바이오로직스 아게 | 변형된 ace2 폴리펩티드 |
| US11058750B2 (en) * | 2015-12-03 | 2021-07-13 | Mor Research Applications Ltd. | Compositions and methods for treatment of ocular diseases |
| NZ788906A (en) * | 2016-06-01 | 2025-07-25 | Servier Ip Uk Ltd | Formulations of polyalkylene oxide-asparaginase and methods of making and using the same |
| WO2023119230A1 (en) | 2021-12-22 | 2023-06-29 | L'oreal | Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4775624A (en) * | 1985-02-08 | 1988-10-04 | Eli Lilly And Company | Vectors and compounds for expression of human protein C |
| US4849403A (en) * | 1985-05-29 | 1989-07-18 | Pentapharm Ag | Protein C activator, methods of preparation and use thereof |
| US5516650A (en) * | 1985-06-27 | 1996-05-14 | Zymogenetics, Inc. | Production of activated protein C |
| DE3607559A1 (de) * | 1986-03-07 | 1987-09-10 | Boehringer Mannheim Gmbh | Verfahren zur photometrischen bestimmung der protein c- und/oder protein s-aktivitaet |
| AT399095B (de) * | 1986-03-27 | 1995-03-27 | Vukovich Thomas Dr | Verfahren zur auftrennung von proteinen mittels gradientenelution und vorrichtung zur durchführung des verfahrens |
| US5175087A (en) * | 1987-07-06 | 1992-12-29 | Biopool International, Inc. | Method of performing tissue plasminogen activator assay |
| US4877608A (en) * | 1987-11-09 | 1989-10-31 | Rorer Pharmaceutical Corporation | Pharmaceutical plasma protein formulations in low ionic strength media |
| US4992373A (en) * | 1987-12-04 | 1991-02-12 | Eli Lilly And Company | Vectors and compounds for direct expression of activated human protein C |
| JP2739050B2 (ja) * | 1988-01-28 | 1998-04-08 | ヘキスト薬品工業株式会社 | 抗血液凝固剤 |
| US4981952A (en) * | 1988-10-04 | 1991-01-01 | Eli Lilly And Company | Method for the purification of vitamin K-dependent proteins |
| US5093117A (en) * | 1989-01-24 | 1992-03-03 | Baxter International Inc. | Compositions and method for the treatment or prophylaxis of sepsis or septic shock |
| AT402262B (de) * | 1991-06-20 | 1997-03-25 | Immuno Ag | Arzneimittel enthaltend aktiviertes protein c |
| US5413732A (en) * | 1991-08-19 | 1995-05-09 | Abaxis, Inc. | Reagent compositions for analytical testing |
| MY110664A (en) * | 1992-05-21 | 1999-01-30 | Lilly Co Eli | Protein c derivatives |
| DE4234295A1 (de) * | 1992-10-12 | 1994-04-14 | Thomae Gmbh Dr K | Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| US5395923A (en) * | 1993-02-23 | 1995-03-07 | Haemacure-Biotech, Inc. | Process for the obtention of a biological adhesive made of concentrated coagulation factors by "salting-out" |
| JP3043558B2 (ja) * | 1993-10-29 | 2000-05-22 | 財団法人化学及血清療法研究所 | ヒト活性化プロテインc調製物及びその製法 |
| JP2886061B2 (ja) * | 1993-10-29 | 1999-04-26 | 財団法人化学及血清療法研究所 | プロテインcもしくは活性化プロテインcの安定化方法及び安定化組成物 |
| PL195642B1 (pl) * | 1997-04-28 | 2007-10-31 | Lilly Co Eli | Sposób przetwarzania wodnego roztworu aktywowanego białka C |
| US6630137B1 (en) * | 1997-04-28 | 2003-10-07 | Eli Lilly And Company | Activated protein C formulations |
| AT409334B (de) * | 1997-09-19 | 2002-07-25 | Immuno Ag | Pharmazeutisches präparat enthaltend vitamin k-abhängige einzelfaktoren |
| HUP0001237A3 (en) * | 1997-10-20 | 2002-01-28 | Lilly Co Eli | Methods for treating vascular disorders |
| JP2004535461A (ja) * | 2001-07-19 | 2004-11-25 | ディーエムアイ バイオサイエンシズ インコーポレイテッド | プロテインcの不活性化を抑制するための銅キレート剤の使用 |
-
2003
- 2003-02-27 CA CA002475738A patent/CA2475738A1/en not_active Abandoned
- 2003-02-27 WO PCT/US2003/005046 patent/WO2003075834A2/en not_active Ceased
- 2003-02-27 JP JP2003574110A patent/JP2005528351A/ja active Pending
- 2003-02-27 EP EP03709192A patent/EP1485121A4/en not_active Withdrawn
- 2003-02-27 AU AU2003213146A patent/AU2003213146A1/en not_active Abandoned
- 2003-02-27 US US10/506,301 patent/US20050143283A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2288143A1 (en) | Activated protein c formulations | |
| JP2005526084A5 (enExample) | ||
| JP2003522154A5 (enExample) | ||
| JP2009524595A5 (enExample) | ||
| JP2006523695A5 (enExample) | ||
| JP2005519914A5 (enExample) | ||
| JP2019509311A5 (enExample) | ||
| JP2015535237A5 (enExample) | ||
| JP2024099628A5 (enExample) | ||
| ES2224917T1 (es) | Composiciones farmaceuticas de agente fibrinolitico. | |
| RU2009143991A (ru) | Композиция клопидогреля и сульфоалкилового эфира циклодекстрина (варианты) и способы лечения заболеваний посредством названной композиции (варианты) | |
| EP2197283B1 (en) | Formulations for preservation of rota virus | |
| JP2014139229A5 (enExample) | ||
| BRPI0409450B8 (pt) | composições farmacêuticas, úteis para o tratamento ou controle de infecções bacterianas por administração parenteral, processos para a sua produção e respectivos usos | |
| JP2010513487A5 (enExample) | ||
| JP2005528351A5 (enExample) | ||
| JP2003505482A (ja) | ロタウイルスワクチン調合物 | |
| JP2015134795A5 (enExample) | ||
| JP2019512012A5 (enExample) | ||
| JP2002249441A (ja) | 血液凝固第vii因子を活性化するプロテアーゼ又はそのプロ酵素の安定化された液体製剤 | |
| JP2009502972A (ja) | タンパク質凝集を抑制する製剤 | |
| RU2004133349A (ru) | Жидкий препарат, содержащий производное кампототецина, и фармацевтическая композиция, получаемая путем лиофилизации препарата | |
| JP4332694B2 (ja) | 水溶性乾燥組成物 | |
| ES2343432T3 (es) | Preparado granular que contiene un compuesto de biguanida. | |
| JP2003522782A5 (enExample) |